通过调节JAK2-STAT3-SOCS3通路,通过抑制IL-6表达来改善DSS诱导的IBD
Jing Xu1, Wen-Rui Peng2, Die Zhang3
1School of Medicine, Tongji University, Shanghai 200092, People's Republic of China; Research Center for Marine Drugs, Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China.
International immunopharmacology
|February 13, 2024
概括
海洋衍生的化物光胺 (AC14) 通过抑制IL-6的产生和通过JAK2-STAT3-SOCS3通路改善肠道屏障功能,有效治疗炎症性肠病 (IBD).
科学领域:
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病 (IBD) 的发病包括复杂的免疫失调.
- 在IBD中,新型化合物如蓝胺 (AC14) 的治疗潜力需要进一步研究.
- 了解AC14在调节炎性介质中的作用至关重要.
研究的目的:
- 为了研究cyanogramide (AC14) 对炎症性肠病 (IBD) 的治疗作用.
- 在IBD模型中阐明AC14作用的潜在分子机制.
- 评估AC14对细胞因子生产和肠道微生物群的影响.
主要方法:
- 在体外测试中使用THP-1细胞和Caco-2/THP-1共同培养来评估细胞因子释放 (IL-6,TNF-α).
- 使用硫酸 (DSS) 诱导的大肠炎小鼠模型进行体内研究,以评估治疗疗效.
- 对JAK2-STAT3-SOCS3信号通路激活和肠道微生物群组成的分析.
主要成果:
- 在体外和体内,AC14显著抑制了INTERLEUKIN-6 (IL-6) 的释放.
- 在DSS诱导的大肠炎小鼠中,AC14治疗改善了体重,结肠长度和肠壁完整性.
- AC14抑制了血清IL-6,调节了肠道微生物群,并抑制了JAK2-STAT3酸化,同时上调SOCS3表达.
结论:
- 光胺 (AC14) 在炎症性肠病 (IBD) 中显示出显著的治疗潜力.
- AC14通过准JAK2-STAT3-SOCS3信号通路来发挥其抗炎作用.
- AC14代表了IBD治疗的有前途的新药,需要进一步的临床研究.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
01:17Drugs for Treatment of Diarrhea-Predominant IBS
170
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
170
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
164
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
164
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.1K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K